Cibc World Market Inc. Buys 647,763 Shares of DENTSPLY SIRONA Inc. $XRAY

Cibc World Market Inc. boosted its position in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 120.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,184,303 shares of the medical instruments supplier’s stock after purchasing an additional 647,763 shares during the quarter. Cibc World Market Inc.’s holdings in DENTSPLY SIRONA were worth $13,537,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Arizona State Retirement System increased its holdings in DENTSPLY SIRONA by 1.4% during the 3rd quarter. Arizona State Retirement System now owns 58,952 shares of the medical instruments supplier’s stock worth $748,000 after purchasing an additional 807 shares during the period. Empowered Funds LLC increased its holdings in DENTSPLY SIRONA by 8.8% during the 1st quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock worth $244,000 after purchasing an additional 1,320 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in DENTSPLY SIRONA during the 1st quarter worth $26,000. Brevan Howard Capital Management LP increased its holdings in DENTSPLY SIRONA by 9.9% during the 2nd quarter. Brevan Howard Capital Management LP now owns 20,002 shares of the medical instruments supplier’s stock worth $318,000 after purchasing an additional 1,800 shares during the period. Finally, Huntington National Bank increased its holdings in DENTSPLY SIRONA by 68.3% during the 4th quarter. Huntington National Bank now owns 4,689 shares of the medical instruments supplier’s stock worth $54,000 after purchasing an additional 1,903 shares during the period. 95.70% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

XRAY has been the topic of several research reports. Bank of America upgraded DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $13.00 to $17.00 in a report on Thursday, February 19th. Zacks Research upgraded DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a report on Monday, March 2nd. Barclays lowered their price objective on DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating for the company in a research report on Thursday. UBS Group lowered their price objective on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Finally, Barrington Research raised their price objective on DENTSPLY SIRONA from $14.00 to $17.00 and gave the stock an “outperform” rating in a research report on Monday, March 2nd. Three research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $13.55.

Insider Transactions at DENTSPLY SIRONA

In other news, Director James D. Forbes purchased 5,000 shares of the stock in a transaction on Monday, March 9th. The stock was bought at an average price of $12.48 per share, with a total value of $62,400.00. Following the transaction, the director owned 10,000 shares in the company, valued at $124,800. The trade was a 100.00% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gregory T. Lucier purchased 15,000 shares of the stock in a transaction on Monday, March 9th. The shares were purchased at an average cost of $12.45 per share, with a total value of $186,750.00. Following the transaction, the director owned 65,000 shares in the company, valued at $809,250. This trade represents a 30.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 0.46% of the company’s stock.

DENTSPLY SIRONA Stock Performance

Shares of XRAY opened at $10.00 on Friday. The stock has a 50-day moving average of $11.11 and a two-hundred day moving average of $11.71. DENTSPLY SIRONA Inc. has a one year low of $9.40 and a one year high of $17.09. The company has a debt-to-equity ratio of 1.52, a quick ratio of 0.98 and a current ratio of 1.53. The stock has a market cap of $2.00 billion, a P/E ratio of -3.17, a P/E/G ratio of 1.17 and a beta of 0.89.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). DENTSPLY SIRONA had a positive return on equity of 18.83% and a negative net margin of 17.06%.The firm had revenue of $880.00 million for the quarter, compared to analyst estimates of $841.80 million. During the same period in the prior year, the firm posted $0.43 EPS. The business’s revenue was up .1% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, research analysts predict that DENTSPLY SIRONA Inc. will post 1.42 EPS for the current year.

DENTSPLY SIRONA Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.